The Influence To VEGF And Clinical Efficacy Of Patients With Advance Non Small Cell Lung Cancer Accepting Chemotherapy Combined With Shenmai Injection

Object i vesTo observe the changes of vascular endothelial growth factor(VEGF) progression-free survival (PFS), one year survival rate and the the clinic efficacy of the patients with advanced non-small-cell lung cancer(NSCLC) before and after the treatment of chemotherapy with Shenmai Injection. Besides, we also compare immunity, quality of life, the sever sides effects and so on. Through the study, we could provide the evidence that using chemotherapy combined with Shenmai Injection is an effective mean to treat NSCLC.MethodsThis study is a randomized controlled, prospective, single blind trial. 63 eligible patients with NSCLC were divided into two groups-the experiment group and the control group. In this study,32 patients belonged to the experiment group and 31 patients belonged to the control group. The patients in experiment accepted chemotherapy with Shenmai Injection, and the patients in control group accepted chemotherapy as treatment only.The therapeutic effect evaluation was the estimation of the tumor, one year survival rate, Progression-Free-Survival (PFS),the value of VEGF, CEA, SCC, and Performance Status, the score of Chinese clinical symptoms were also measured. Besides, the adverse effect rates were also compared between the two groups after the treatment.ResultIn experiment group, the change of VEGF before and after the treatment was significant difference(P<0.05). However, the change of the VEGF was not significant difference (P>0.05) in control group.The PFS of patients in experiment group was longer than in the control group (5.0 months VS.3.9 months, P<0.05). One year survival rates in experiment group was better than in control group, although the difference was not significant(46.9% VS 41.9%, P>0.05).In both groups, the decrease of the score of Chinese clinical symptoms before and after the treatment was significant(P<0.05). However, the difference in experiment group is more significant than in the control group(P>0.05).The ORR(Objective-Response-Rate) was 32.25% in experiment group and 22.58% in control group, and the DCR(Disease-Control-Rate) was 75% in experiment group and 64.51% in control group (P>0.05).The changes of Performance Status and the T achroacyte subgroup weren’t significant difference before and after the treatment both the two groups(P >0.05).The the adverse effect rates the adverse effect rates show no significant difference between the two groups.ConclusionThe Shenmai Injection with chemotherapy can prolong PFS and influence the VEGF of patients with NSCLC, and the decrease of VEGF may be one kind of anticancer mechanism.The Shenmai Injection with chemotherapy may bring a better one year survival rate than chemotherapy.The Shenmai Injection with chemotherapy can improve the quality of life in patients with NSCLC.The Shenmai Injection with chemotherapy shows no significant advantage on Performance Status and T achroacyte subgroup than chemotherapy.The Shenmai Injection with chemotherapy is a safety kind of treatment.